Open AccessRisk of Virological Failure and Drug Resistance During First and Second-Line Antiretroviral Therapy in a 10-Year Cohort in Senegal
Author(s) -
Pierre De Beaudrap,
Moussa Thiam,
Amadou Diouf,
Coumba Touré-Kâne,
Ndèye Fatou Ngom-Guèye,
Nicole Vidal,
Souleymane Mboup,
Ibrahim Ndoye,
Papa Salif Sow,
Eric Delaporte
Publication year - 2013
Publication title -
journal of acquired immune deficiency syndromes
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.162
H-Index - 157
eISSN - 1944-7884
pISSN - 1525-4135
DOI - 10.1097/qai.0b013e31827a2a7a
Subject(s) - medicine , indinavir , viral load , regimen , cohort , drug resistance , cohort study , protease inhibitor (pharmacology) , hiv drug resistance , virology , antiretroviral therapy , human immunodeficiency virus (hiv) , biology , microbiology and biotechnology
In 1998, Senegal launched one of Africa's first antiretroviral therapy (ART) programs. Since then, the number of treated patients in Africa has substantially increased thanks to simplification in treatment management. Although good outcomes over the first years of ART have been observed in sub-Saharan Africa, little is known about the long-term (>5 years) risks of virological failure and drug resistance and about second-line treatment response.